{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:09:24Z","timestamp":1761293364874},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T00:00:00Z","timestamp":1454457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT02068222"],"award-info":[{"award-number":["NCT02068222"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background &amp; Aims<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\u2010530 is a next\u2010generation hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5A inhibitor with potent pangenotypic antiviral activity <jats:italic>in vitro<\/jats:italic>. Paritaprevir is an <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>3\/4A protease inhibitor codosed with ritonavir that displays <jats:italic>in vitro<\/jats:italic> activity against <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotypes 1\u20134 and 6.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Efficacy, pharmacokinetics and safety of <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\u2010530 with paritaprevir\/ritonavir and ribavirin were evaluated in this phase 2, open\u2010label, multicentre study in treatment\u2010na\u00efve non\u2010cirrhotic patients with genotype 3 infection. Ten patients, all genotype 3a, received 120 mg <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\u2010530 and 150\/100 mg paritaprevir\/ritonavir once daily with ribavirin for 12 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine (90%) patients achieved a sustained virological response at post\u2010treatment weeks 12 and 24. One patient experienced virological failure at treatment week 6. Sequence analyses for <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> variants in samples from this patient identified A166S in <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>3 at baseline and after breakthrough, as well as A30K at baseline and linked S24F+M28K+A30K variants in <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5A after breakthrough. Neither genotype 3 <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>3 A166S nor <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5A A30K variant confers any resistance to paritaprevir or <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\u2010530 respectively. However, genotype 3 <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5A S24F+M28K+A30K\u2010linked variant confers a &gt;5000\u2010fold increase in <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\u2010530 <jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content><jats:sub>50<\/jats:sub> relative to that of the wild\u2010type replicon. This patient's <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\u2010530 exposure was comparable to the cohort, while paritaprevir and ritonavir exposures were the lowest of all patients. No serious or severe adverse events and adverse events leading to early discontinuation were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Results from this study show that <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\u2010530 holds promise as part of a direct\u2010acting antiviral treatment regimen for <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 3 infection.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.13067","type":"journal-article","created":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T12:10:26Z","timestamp":1453119026000},"page":"1125-1132","source":"Crossref","is-referenced-by-count":14,"title":["High antiviral activity of <scp>NS<\/scp>5A inhibitor <scp>ABT<\/scp>\u2010530 with paritaprevir\/ritonavir and ribavirin against hepatitis C virus genotype 3 infection"],"prefix":"10.1111","volume":"36","author":[{"given":"Fred","family":"Poordad","sequence":"first","affiliation":[{"name":"Texas Liver Institute University of Texas Health Science Center San Antonio TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles S.","family":"Landis","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology University of Washington Seattle WA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armen","family":"Asatryan","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Daniel F.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Digestive Health Specialists of the Southeast Dothan AL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa I.","family":"Ng","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Fu","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih\u2010Wei","family":"Lin","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty","family":"Yao","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kort","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,2,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12646"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7085"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2004.08.001"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/524846"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26905"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01441.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01634.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12168"},{"key":"e_1_2_8_12_1","unstructured":"SOVALDI (sofosbuvir).Prescribing Information.Gilead Sciences.Foster City CA 2014."},{"key":"e_1_2_8_13_1","unstructured":"DAKLINZA (daclatasvir).Summary of Product Characteristics.Bristol\u2010Myers Squibb.Uxbridge UK 2014."},{"key":"e_1_2_8_14_1","unstructured":"DAKLINZA (daclatasvir).Prescribing Information.Bristol\u2010Myers Squibb New York City NY 2015."},{"key":"e_1_2_8_15_1","unstructured":"HARVONI (ledipasvir and sofosbuvir).Summary of Product Characteristics.Gilead Sciences Cambridge UK 2015."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30009-X"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03763.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0381-2"},{"key":"e_1_2_8_21_1","unstructured":"MenonRM KleinCE LawalAA et al.Pharmacokinetics and Tolerability of the HCV Protease Inhibitor ABT\u2010450 Following Single Ascending Doses in Healthy Adult Volunteers With and Without Ritonavir.HepDART Kohala Coast HI 2009."},{"key":"e_1_2_8_22_1","unstructured":"VIEKIRA PAK (ombitasvir paritaprevir\/ritonavir dasabuvir).Prescribing Information.AbbVie Inc. North Chicago IL 2015."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.09.008"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04227-14"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04226-14"},{"key":"e_1_2_8_26_1","unstructured":"NgT KrishnanP KatiW et al.ABT\u2010530 an HCV NS5A inhibitor with potent pangenotypic activity and high genetic barrier to resistance. Abstract 639.21st Annual Conference on Retroviruses and Opportunistic Infections.Boston 2014."},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30979-X"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01229-15"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02264-15"},{"key":"e_1_2_8_30_1","first-page":"15","article-title":"A 4\u2010drug combination (Viekira Pak) for hepatitis C","volume":"57","year":"2015","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01320-07"},{"key":"e_1_2_8_32_1","unstructured":"NgT ReischT MiddletonT et al.ABT\u2010493 a potent HCV NS3\/4A protease inhibitor with broad genotypic coverage. Abstract 636.21st Annual Conference on Retroviruses and Opportunistic Infections.Boston 2014."},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.01.011"},{"key":"e_1_2_8_34_1","first-page":"1142A","article-title":"A next generation HCV DAA combination: potent, pangenotypic inhibitors ABT\u2010493 and ABT\u2010530 with high barriers to resistance","volume":"60","author":"Ng T","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i11.2902"},{"key":"e_1_2_8_36_1","unstructured":"National Institutes of Health National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.2009. Available at:http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 18 December 2014."},{"key":"e_1_2_8_37_1","first-page":"1128A","article-title":"Potent antiviral activity of ABT\u2010493 and ABT\u2010530 with 3\u2010day monotherapy in patients with and without compensated cirrhosis with hepatitis C virus (HCV) genotype 1 infection","volume":"60","author":"Lawitz EJ","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_8_38_1","first-page":"236A","article-title":"Once daily sofosbuvir with GS\u20105816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR12: the ELECTRON2 study. Abstract #79","volume":"60","author":"Gane E","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30013-1"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13067","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.13067","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:42:42Z","timestamp":1695512562000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,3]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/liv.13067"],"URL":"https:\/\/doi.org\/10.1111\/liv.13067","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,3]]}}}